Listen Now

AUA2023: Genetics and Genomics of GU Malignancies: Applications into Your Clinical Practice CME Available: https://auau.auanet.org/node/38317 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: AUA Guidelines on Advanced Prostate Cancer CME Available: https://auau.auanet.org/node/38297 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: Diversity, Equity and Inclusion in Urology: What Do We Need to Know CME Available: https://auau.auanet.org/node/38332/ ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc.

AUA2023: The Changing Face of Advanced Prostate Cancer CME Available: https://auau.auanet.org/node/38292 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: Contemporary Pharmacotherapy for OAB 2023 CME Available: https://auau.auanet.org/node/38282 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas Urovant Sciences, Inc. LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for OAB. 2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta3 agonists and combination therapy. 3. Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies. 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents. 5. Discuss potential future pharmacological pathways and therapies for OAB.

Live from AUA2023: Highlights in BPH is a panel discussion filmed during the 2023 AUA Annual Meeting! This activity is designed to increase the urologist’s understanding of how to translate the latest scientific advances into their routine clinical practice, improving the care of patients with BPH. CME Available: https://auau.auanet.org/node/38008 ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Cook Medical, LLC. Olympus Corporation of the Americas

Live from AUA2023: Highlights in Advanced Prostate Cancer is a panel discussion filmed during the 2023 AUA Annual Meeting! CME Available: https://auau.auanet.org/node/38002 This activity is designed to increase the urologist’s understanding of how to translate the latest scientific advances into their routine clinical practice, improving the care of patients with advanced prostate cancer. Faculty will review the latest advances in prostate cancer including the many new FDA-approved agents, as well as existing standard therapies. Urologists will gain the ability to translate the latest scientific advances into their routine clinical practice, improving the care of men with advanced prostate cancer. At the conclusion of the activity, participants will be able to: 1. Describe recent developments in the medical management of advanced prostate cancer. 2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC. 3. Discuss clinical investigations in the treatment of advanced prostate cancer. 4. Analyze the risks and benefits of treatment for advanced prostate cancer. 5. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas and Pfizer, Inc. AstraZeneca Merck & Co., Inc.

The Role of PARP Inhibitors in Advanced Prostate Cancer CME Available: https://auau.auanet.org/node/38241 Based on the documented need from the most recent AUA needs assessment in advanced prostate cancer, this symposium will address the role of PARP Inhibitor treatment, as well as evidence and outcomes of PARP Inhibitors as outlined in the newly amended Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline. At the conclusion of this activity, participants will be able to: 1. Review recommended criteria for genetic testing of prostate cancer patients and how to interpret these tests. 2. Explain the role of the enzyme poly ADP ribose polymerase (PARP) in carcinogenesis as well as the mechanism of PARP inhibition for cancer treatment. 3. Describe the role of PARP Inhibitor treatment alone and in combination with androgen receptor targeted therapies. 4. Review the evidence and outcomes on PARP Inhibitors as outlined in the newly amended Advanced Prostate Cancer: AUA/SUO Guideline. 5. Discuss clinical trial data assessing the efficacy of PARP inhibitors in advanced prostate cancer, including patient populations and clinical outcomes for each trial. ACKNOWLEDGEMENT This educational activity is supported by independent educational grants from: Pfizer, Inc.

Complications of Vaginal Mesh Course Director: Kamran Sajadi, MD Course Faculty: Farzeen Firoozi, MD Christopher F. Tenggardjaja, MD

Course Director: Warren T. Snodgrass, MD Course Faculty: Nicol C. Bush, MD, MCS

AUA Urology Core Curriculum: auau.auanet.org/core Host: Jay D. Raman, MD, FACS Co-Host: Sean Elliott, MD Outline: 1. Are the terms “transitional urology” and “adult congenital urology” synonymous 2. What are the unique challenges in transitional urology 3. Why does spina bifida seem to dominate the transitional urology landscape 4. Exstrophy 5. Counseling pregnant women with a congenital urological condition 6. How does posterior urethral valve bladder present in adulthood

Update Series (2023) Lesson 4: Difficult Foleys and Foley Difficulties Now in its 42nd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information, please visit the AUA Update Series on the AUAUniversity: https://auau.auanet.org/update23

AUA2022: Evaluation and Management of Priapism Course Director: Martin Gross, MD Course Faculty: Trinity J. Bivalacqua MD, PhD Jay Simhan, MD, FACS Faysal A. Yafi, MD, FRCSC

This episode is brought to you by the AUA Leadership & Business Podcast Subscribe today by searching “AUA Leadership & Business” on your favorite podcast app. Host: Jennifer Miles-Thomas, MD, FPMRS Guest: Jaspreet S. Sandhu, MD

Modernizing Urology Care: The Current and Future State of Virtual Care in the United States Host: Jay D. Raman, MD, FACS Guest: Chad Ellimoottil, MD, MS

Health Equities and Variations in Advanced Prostate Cancer Care CME Available: https://auau.auanet.org/node/37728 LEARNING OBJECTIVES: At the conclusion of these activities, participants will be able to: 1. Identify the impact of race and cultural barriers for ethnic minorities on medical clinical care specific to advanced prostate cancer. 2. Evaluate financial toxicity as a barrier to optimal patient care specific to advanced prostate cancer. 3. Incorporate culturally sensitive communications to ensure quality care and reduce biases across diverse patient populations. ACKNOWLEDGEMENTS: This series is supported by independent educational grants from:  Myovant Sciences LTD Pfizer, Inc.

Comorbid Conditions in the Patient with Advanced Prostate Cancer CME Available: https://auau.auanet.org/node/37727 LEARNING OBJECTIVES: At the conclusion of these activities, participants will be able to: 1. Oversee comorbidities and describe their management in the context of advanced prostate cancer treatment. 2. Assess the potential cardiovascular risk associated with ADT. 3. Differentiate the roles of the urologist, other specialists and advanced practice providers and identify opportunities for shared care and team-based approaches of patients with prostate cancer. ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Myovant Sciences LTD Pfizer, Inc.

Advances in ADT: A Guide for Urologists and APPs CME Available: https://auau.auanet.org/node/37866 At the conclusion of this activity, participants will be able to: 1. Identify and treat a patient with new diagnosed M1 prostate cancer with ADT plus be able to offer additional therapies that extend survival. 2. Analyze the risks and benefits of treatment for M1 HSPC, MO CRPC, and M1 CRPC. 3. Differentiate the clinical significance of GnRH agonists vs. GnRH antagonists and newer treatments that complement these options. 4. Identify opportunities for shared care and team-based approaches of patients with advanced prostate cancer. 5. Facilitate discussions with patients and caregivers regarding ADT and advanced prostate cancer treatment. ACKNOWLEDGEMENTS Independent educational grant support provided by: Myovant Sciences LTD Pfizer Inc.

AUA2022 JU Lecture: Engaging Patients: A Challenge to our Care Delivery and Research Priorities Speaker: Angela Smith, MD, MS University of North Carolina at Chapel Hill

AUA2022 Ramon Guiteras Lecture: How to Reach Excellence in Urology: Challenges and Opportunities Speaker: Francesco Montorsi, MD